Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib (‘Iressa’, ZD1839) and erlotinib (‘Tarceva’, OSI-774), and the monoclonal antibody cetuximab ...

Iressa was fast-tracked to the FDA and received approval May 5, 2003 as a single agent treatment for patients whose advanced lung cancer had continued to progress despite treatment with platinum ...

The LoVo human colorectal carcinoma cell line was obtained from ECACC. All cell culture reagents were obtained from Gibco BRL. Cells were maintained in RPMI medium supplemented with 10% foetal ...

Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

HOUSTON - Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of ...

said Monday that its experimental cancer drug, Iressa, when given with standard chemotherapy, failed to improve the survival rate of lung cancer patients in two large, late-stage clinical trials.

AstraZeneca 's Iressa can help patients recover from lung cancers that would otherwise be deadly. Unfortunately the drug, which was approved by the Food and Drug Administration today, works only ...

There she ran across a pill called Iressa. Though not sold yet, it was available in some desperate cases like hers. Iressa is one of a new class of medicines called epidermal growth factor ...

The U.S. Food and Drug Administration has approved Iressa (gefitinib) for the frontline treatment of patients with metastatic non-small cell lung cancer that is positive for EGFR and has one of two ...

AstraZeneca is to pitch its anticancer offering Iressa (gefitinib) head to head against Roche's Tarceva (erlotinib) in a bid to reinvigorate the profile of its once star offering and put some life ...

drug Iressa for use in patients with advanced lung cancer. Iressa will be used as a stand-alone treatment for non-small-cell lung cancer patients who have failed all other approved treatments.